Joyce Blaisdell

5.3k citations

35 papers · 4.4k indexed · 2 hit papers · h-index 30

Impact in

Pharmacology top 0.02%
- Pharmacogenetics and Drug Metabolism
- Inflammatory mediators and NSAID effects
Biochemistry top 0.5%
- Eicosanoids and Hypertension Pharmacology

Papers in

Pharmacology 26
- Pharmacogenetics and Drug Metabolism 26
Biochemistry 7
- Eicosanoids and Hypertension Pharmacology 7

Co-authors: Joyce A. Goldstein Jorge Goldstein G. Wilkinson Urs Meyer Kōichi Nakamura Burhan I. Ghanayem Sara Moráis Darryl C. Zeldin
Journals: Journal of Pharmacology and Experimental Therapeutics (5 papers)Biochemical and Biophysical Research Communications (4 papers)Molecular Pharmacology (2 papers)Journal of Biological Chemistry (2 papers)European Journal of Clinical Pharmacology (2 papers)
Partner nations: United States China Russia

In The Last Decade

Joyce Blaisdell

35 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. 1994 · 649 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1994 Molecular Pharmacology
1994 Journal of Biological Chemistry

Peers

Countries citing papers authored by Joyce Blaisdell

Since Specialization

Citations

This map shows the geographic impact of Joyce Blaisdell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Blaisdell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Blaisdell more than expected).

Fields of papers citing papers by Joyce Blaisdell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Blaisdell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Blaisdell. The network helps show where Joyce Blaisdell may publish in the future.

Co-authors

The 25 scholars most cited alongside Joyce Blaisdell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joyce Blaisdell Line = papers co-authored together Joyce Blaisdell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cyclophosphamide and 4‐hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis British Journal of Clinical Pharmacology ·Melanie S. Joy, Mary K. La, Jinzhao Wang, Arlene S. Bridges, Yichun Hu, Susan L. Hogan, Reginald F. Frye, Joyce Blaisdell, Joyce A. Goldstein, Mary Anne Dooley, Kim L. R. Brouwer, Ronald J. Falk	2012	43
2	CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases European Journal of Clinical Pharmacology ·Melanie S. Joy, Kimberly A. Dornbrook-Lavender, Joyce Blaisdell, Tandrea Hilliard, Tammy Boyette, Yichun Hu, Susan L. Hogan, Corina Candiani, Ronald J. Falk, Joyce A. Goldstein	2009	26
3	Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450 Journal of Pharmacology and Experimental Therapeutics ·Piyush M. Vyas, Sanjoy Roychowdhury, Farah Khan, Thomas E. Prisinzano, Jatinder K. Lamba, Erin G. Schuetz, Joyce Blaisdell, Joyce A. Goldstein, Kimber L. Munson, Ronald N. Hines, Craig K. Svensson	2006	33
4	Discovery of new potentially defective alleles of human CYP2C9 Pharmacogenetics ·Joyce Blaisdell, Lucia F. Jorge-Nebert, Sherry J. Coulter, Stephen Ferguson, Su‐Jun Lee, Brian Chanas, Tina Xi, Harvey W. Mohrenweiser, Burhan I. Ghanayem, Joyce A. Goldstein	2004	124
5	Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C91/1, 1/2 , and 1/3 Individuals Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Craig R. Lee, John A. Pieper, Alan L. Hinderliter, Joyce Blaisdell, Joyce A. Goldstein	2003	30
6	Differences in flurbiprofen pharmacokinetics between CYP2C91/1, 1/2, and 1/3 genotypes European Journal of Clinical Pharmacology ·Craig R. Lee, John A. Pieper, Reginald F. Frye, Alan L. Hinderliter, Joyce Blaisdell, Joyce A. Goldstein	2003	53
7	Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans The Journal of Clinical Pharmacology ·Craig R. Lee, John A. Pieper, Alan L. Hinderliter, Reginald F. Frye, Joyce Blaisdell, Joyce A. Goldstein	2003	79
8	Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin Pharmacogenetics ·Robert S. Kidd, Timothy B. Curry, Susan Gallagher, Timi Edeki, Joyce Blaisdell, Joyce A. Goldstein	2001	196
9	Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics ·Ding Dai, Darryl C. Zeldin, Joyce Blaisdell, Brian Chanas, Sherry J. Coulter, Burhan I. Ghanayem, Joyce A. Goldstein	2001	403
10	A Novel Transversion in the Intron 5 Donor Splice Junction of CYP2C19 and a Sequence Polymorphism in Exon 3 Contribute to the Poor Metabolizer Phenotype for the Anticonvulsant Drug S-Mephenytoin Journal of Pharmacology and Experimental Therapeutics ·Gordon C. Ibeanu, Joyce Blaisdell, Ronald J. Ferguson, Burhan I. Ghanayem, Kim Brøsen, Simone Benhamou, Christine Bouchardy, G. Wilkinson, Pierre Dayer, Joyce A. Goldstein	1999	87
11	Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C93 allele Pharmacogenetics* ·Robert S. Kidd, Arthur B. Straughn, Marvin C. Meyer, Joyce Blaisdell, Joyce A. Goldstein, James T. Dalton	1999	130
12	Gene structure ofCYP2C8 and extrahepatic distribution of the human CYP2Cs Journal of Biochemical and Molecular Toxicology ·Theresa S. Klose, Joyce Blaisdell, Joyce A. Goldstein	1999	152
13	An additional defective allele, CYP2C195, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians Pharmacogenetics* ·Gordon C. Ibeanu, Joyce Blaisdell, Burhan I. Ghanayem, Christine Beyeler, Simone Benhamou, Christine Bouchardy, G. Wilkinson, Pierre Dayer, Ann K. Daly, Joyce A. Goldstein	1998	79
14	Cloning and Expression of Murine CYP2Cs and Their Ability to Metabolize Arachidonic Acid Archives of Biochemistry and Biophysics ·Gang Luo, Darryl C. Zeldin, Joyce Blaisdell, Ernest Hodgson, Joyce A. Goldstein	1998	97
15	Identification of New Human CYP2C19 Alleles (CYP2C196 and CYP2C192B) in a Caucasian Poor Metabolizer of Mephenytoin Journal of Pharmacology and Experimental Therapeutics ·Gordon C. Ibeanu, Joyce A. Goldstein, Urs Meyer, Simone Benhamou, Christine Bouchardy, Pierre Dayer, Burhan I. Ghanayem, Joyce Blaisdell	1998	104
16	[23] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism Methods in enzymology on CD-ROM/Methods in enzymology ·Joyce A. Goldstein, Joyce Blaisdell	1996	104
17	Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology ·Sara Moráis, G. Wilkinson, Joyce Blaisdell, Urs Meyer, Kōichi Nakamura, Jorge Goldstein Hit paper breakdown →	1994	649
18	Gene Structure and Upstream Regulatory Regions of Human CYP2C9 and CYP2C18 Biochemical and Biophysical Research Communications ·S.M.F. Demorais, Helmut Schweikl, Joyce Blaisdell, Jorge Goldstein	1993	49
19	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily Biochemistry ·Marjorie Romkes, M B Faletto, Joyce Blaisdell, Judy L. Raucy, Jorge Goldstein	1991	178
20	Transient activation of C-MYC protooncogene expression in leydig cells by human chorionic gonadotropin Biochemical and Biophysical Research Communications ·T. Lin, Joyce Blaisdell, Karen W. Barbour, E. Aubrey Thompson	1988	11

About Joyce Blaisdell

Joyce Blaisdell is a scholar working on Pharmacology, Biochemistry, Transplantation, Reproductive Medicine and Clinical Biochemistry, having authored 35 papers that have together received 4.4k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (26 papers), Eicosanoids and Hypertension Pharmacology (7 papers), Drug Transport and Resistance Mechanisms (7 papers), Analytical Chemistry and Chromatography (4 papers), Metabolism and Genetic Disorders (3 papers), Computational Drug Discovery Methods (3 papers), Metabolomics and Mass Spectrometry Studies (3 papers) and Pharmacological Effects and Toxicity Studies (2 papers). The work is most often cited by research in Pharmacology (2.8k citations), Biochemistry (589 citations), Oncology (1.6k citations), Gastroenterology (290 citations) and Endocrinology, Diabetes and Metabolism (697 citations). Joyce Blaisdell has collaborated with scholars based in United States, China and Russia. Frequent co-authors include Joyce A. Goldstein, Jorge Goldstein, G. Wilkinson, Urs Meyer, Kōichi Nakamura, Burhan I. Ghanayem, Sara Moráis, Darryl C. Zeldin, Brian Chanas and Sherry J. Coulter. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Biochemical and Biophysical Research Communications, Molecular Pharmacology, Journal of Biological Chemistry and European Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact